Literature DB >> 23610543

The unmet need of stroke prevention in atrial fibrillation in the far East and South East Asia.

Yutao Guo1, Gregory Y H Lip, Stavros Apostolakis.   

Abstract

The prevalence of atrial fibrillation (AF) is high in both community- and hospital-based studies in the Far East and South East Asia. Hypertension is the most common risk factor, but coronary heart disease and diabetes mellitus are other important co-morbidities in these countries. Anticoagulant therapy use was low, being 0.5%-28% in Malaysia, Singapore, and China. The reported rate of stroke related to AF was 13.0%-15.4% based on community studies in those countries, and was 3.1%-24.2% of stroke rate in hospital-based cohorts. Better assessment of thromboembolic and bleeding risks is important. International guidelines now recommend the use of the CHA2DS2-VASc score to identify the ''truly low-risk'' AF patients, who do not need antithrombotic therapy, whilst those with ≥ 1 stroke risk factors can be offered oral anticoagulation. Aspirin is ineffective and may not be any safer than oral anticoagulants, especially in the elderly. It is anticipated that the availability of the new oral anticoagulant drugs would improve our efforts for stroke prevention in the Far East and South East Asia, especially where anticoagulation monitoring for warfarin is suboptimal.

Entities:  

Keywords:  Far East; anticoagulation; atrial fibrillaton; burden; stroke

Year:  2012        PMID: 23610543      PMCID: PMC3629658     

Source DB:  PubMed          Journal:  Malays J Med Sci        ISSN: 1394-195X


  17 in total

Review 1.  Atrial fibrillation.

Authors:  Gregory Y H Lip; Hung Fat Tse; Deirdre A Lane
Journal:  Lancet       Date:  2011-12-11       Impact factor: 79.321

2.  The CHADS2 score for stroke risk stratification in atrial fibrillation--friend or foe?

Authors:  G Karthikeyan; J W Eikelboom
Journal:  Thromb Haemost       Date:  2010-05-10       Impact factor: 5.249

3.  Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John J You; Daniel E Singer; Patricia A Howard; Deirdre A Lane; Mark H Eckman; Margaret C Fang; Elaine M Hylek; Sam Schulman; Alan S Go; Michael Hughes; Frederick A Spencer; Warren J Manning; Jonathan L Halperin; Gregory Y H Lip
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

Authors:  Ron Pisters; Deirdre A Lane; Robby Nieuwlaat; Cees B de Vos; Harry J G M Crijns; Gregory Y H Lip
Journal:  Chest       Date:  2010-03-18       Impact factor: 9.410

Review 5.  Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis.

Authors:  Claire Keogh; Emma Wallace; Ciara Dillon; Borislav D Dimitrov; Tom Fahey
Journal:  Thromb Haemost       Date:  2011-07-28       Impact factor: 5.249

6.  The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.

Authors:  Jonas Bjerring Olesen; Christian Torp-Pedersen; Morten Lock Hansen; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2012-04-03       Impact factor: 5.249

7.  Trends in stroke incidence after hospitalization for atrial fibrillation in Sweden 1987 to 2006.

Authors:  Lars G Olsson; Karl Swedberg; Georg Lappas; Simon Stewart; Annika Rosengren
Journal:  Int J Cardiol       Date:  2012-03-30       Impact factor: 4.164

8.  Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study.

Authors:  Jonas Bjerring Olesen; Gregory Y H Lip; Jesper Lindhardsen; Deirdre A Lane; Ole Ahlehoff; Morten Lock Hansen; Jakob Raunsø; Janne Schurmann Tolstrup; Peter Riis Hansen; Gunnar Hilmar Gislason; Christian Torp-Pedersen
Journal:  Thromb Haemost       Date:  2011-07-20       Impact factor: 5.249

9.  Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1.

Authors:  Laurent Gorin; Laurent Fauchier; Emilie Nonin; Axel de Labriolle; Ken Haguenoer; Pierre Cosnay; Dominique Babuty; Bernard Charbonnier
Journal:  Thromb Haemost       Date:  2010-02-02       Impact factor: 5.249

10.  The net clinical benefit of warfarin anticoagulation in atrial fibrillation.

Authors:  Daniel E Singer; Yuchiao Chang; Margaret C Fang; Leila H Borowsky; Niela K Pomernacki; Natalia Udaltsova; Alan S Go
Journal:  Ann Intern Med       Date:  2009-09-01       Impact factor: 25.391

View more
  4 in total

1.  Stroke prevention in atrial fibrillation: the Singapore story.

Authors:  Pow-Li Chia
Journal:  Singapore Med J       Date:  2020-12       Impact factor: 1.858

2.  Knowledge, attitude, and practice regarding atrial fibrillation among primary care physicians: the potential role of postgraduate training.

Authors:  Phaik Choo Ooi; Gogilavendan Ramayah; Syahril Rizwan Omar; Vilasini Rajadorai; Thatsheila Nadarajah; Chung Hui Ting; Cheong Lieng Teng
Journal:  Malays Fam Physician       Date:  2021-02-07

3.  2021 Asia Pacific Heart Rhythm Society (APHRS) practice guidance on atrial fibrillation screening.

Authors:  Ngai-Yin Chan; Jessica Orchard; Michael-Joseph Agbayani; Dean Boddington; Tze-Fan Chao; Sofian Johar; Bobby John; Boyoung Joung; Saravanan Krishinan; Rungroj Krittayaphong; Sayaka Kurokawa; Chu-Pak Lau; Toon Wei Lim; Pham Tran Linh; Vien Hoang Long; Ajay Naik; Yasuo Okumura; Tetsuo Sasano; Bernard Yan; Sunu Budhi Raharjo; Dicky Armein Hanafy; Yoga Yuniadi; Nwe Nwe; Zahid Aslam Awan; He Huang; Ben Freedman
Journal:  J Arrhythm       Date:  2021-12-28

4.  2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation.

Authors:  Chern-En Chiang; Ken Okumura; Shu Zhang; Tze-Fan Chao; Chung-Wah Siu; Toon Wei Lim; Anil Saxena; Yoshihide Takahashi; Wee Siong Teo
Journal:  J Arrhythm       Date:  2017-06-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.